Enhancing Radiofrequency Ablation for Hepatocellular Carcinoma: Nano‐Epidrug Effects on Immune Modulation and Antigenicity Restoration
Advanced Materials · 2024
DOI: 10.1002/adma.202414365 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2024. Verfasst von Xiaocheng Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 1300…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Manganese Compounds, Oxides. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Key Technology Research and Development Program of Shandong Province, Natural Science Foundation of Jilin Province, Innovative Research Group Project of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Radiofrequency ablation (RFA), a critical therapy for hepatocellular carcinoma (HCC), carries a significant risk of recurrence and metastasis, particularly owing to mechanisms involving immune evasion and antigen downregulation via epigenetic modifications. This study introduces a “nano‐epidrug” named MFMP. MFMP, which is composed of hollow mesoporous manganese dioxide (MnO 2 ) nanoparticles, FIDAS‐5 as an MAT2A inhibitor, macrophage membrane, and anti‐PD‐L1 (aPD‐L1), targets HCC cells. By selectively binding to these cells, MFMP initially reverses immune suppression via PD‐L1 inhibition. After endocytosis, MFMP disassembles in the tumor microenvironment, releasing FIDAS‐5 and Mn 2+ . FIDAS‐5 prevents cGAS methylation, whereas Mn 2+ aids STING pathway restoration. In addition, FIDAS‐5 reduces m 6 A RNA modification, suppressing EGFR expression. These changes enhance HCC antigenicity to promote cytotoxic T cell recognition and cytotoxic killing. Furthermore, MFMP mediates immunogenic cell death in HCC by synergizing with RFA through cGAS DNA demethylation, EGFR mRNA demethylation, and TBK1 protein phosphorylation, thereby inhibiting recurrence and metastasis and enhancing immune memory. Thus, MFMP is a potential adjunctive therapy requiring clinical validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, China.
- State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, College of Chemistry, Jilin University, 2699 Qianjin Street, Changchun, 130012, China.
ORCID-Profile: Bai Ji
Förderung
- Key Technology Research and Development Program of Shandong Province
- Natural Science Foundation of Jilin Province
- Innovative Research Group Project of the National Natural Science Foundation of China
Zitieren
APA
Li, X., Liu, Y., Ke, J., Wang, Z., Han, M., Wang, N., Miao, Q., Shao, B., Zhou, D., Yan, F., & Ji, B. (2024). Enhancing Radiofrequency Ablation for Hepatocellular Carcinoma: Nano‐Epidrug Effects on Immune Modulation and Antigenicity Restoration. Advanced Materials. https://doi.org/10.1002/adma.202414365
Vancouver
Li X, Liu Y, Ke J, Wang Z, Han M, Wang N, et al. Enhancing Radiofrequency Ablation for Hepatocellular Carcinoma: Nano‐Epidrug Effects on Immune Modulation and Antigenicity Restoration. Advanced Materials. 2024. doi:10.1002/adma.202414365
BibTeX
@article{Li2024,
author = {Li, Xiaocheng and Liu, Yahui and Ke, Jianji and Wang, Zhihua and Han, Mingda and Wang, Ning and Miao, Qiannan and Shao, Bingru and Zhou, Dan and Yan, Fei and Ji, Bai},
title = {Enhancing Radiofrequency Ablation for Hepatocellular Carcinoma: Nano‐Epidrug Effects on Immune Modulation and Antigenicity Restoration},
journal = {Advanced Materials},
year = {2024},
doi = {10.1002/adma.202414365}
}
EUVIMED